DDC Announces Plans to Offer LAAB to More People

[snoop1130]

 

BANGKOK (NNT) - The Ministry of Public Health has announced plans to offer long-acting antibodies (LAAB) to Covid-19 patients who are at risk of complications, as well as other patient groups.

 

Dr. Sophon Iamsirithaworn, Deputy Director-General of the Department of Disease Control (DDC), stated that studies showed that LAAB, manufactured by Evusheld and administered as pre-infection protection in Thailand, could be used to effectively treat Covid-19 patients while also reducing the impact of the illness on others.

 

Dr. Sophon stated that with Japan and Europe having approved the use of LAAB for vulnerable Covid-19 patients, Thailand is expected to follow suit to protect vulnerable populations who have not contracted Covid-19.

 

When administered within seven days of the onset of symptoms, according to a study published in Lancet Respiratory Medicine, LAAB can reduce Covid-related severe illnesses and deaths by 50 percent. The reduction increases to 67% if administered within five days and to 88% if administered within three days of symptom onset.

 

According to the DDC deputy director-general, more than 3,400 Thais have been given LAAB, which primarily targets patients on dialysis and those who have undergone organ and bone marrow transplants. The antibodies are expected to soon be administered to other patient groups, including those receiving chemotherapy and radiotherapy, those with low antibody levels, and patients on immunosuppressants following transplant and joint surgeries.

 

Source: https://thainews.prd.go.th/en/news/detail/TCATG220922113710941

 

-- © Copyright NNT 2022-09-22

 

- Cigna offers a range of visa-compliant plans that meet the minimum requirement of medical treatment, including COVID-19, up to THB 3m. For more information on all expat health insurance plans click here.

 

Monthly car subscription with first-class insurance, 24x7 assistance and more in one price - click here to find out more!

[rwill]

13 hours ago, snoop1130 said:

LAAB can reduce Covid-related severe illnesses and deaths by 50 percent.

and it tastes good too!!!

[hotchilli]

17 hours ago, snoop1130 said:

The Ministry of Public Health has announced plans to offer long-acting antibodies (LAAB) to Covid-19 patients who are at risk of complications, as well as other patient groups.

One portion of LAAB a day is enough for me.

[connda]

LAAB is cilgavimab and tixagevimab (Evusheld).  Essentially is a monoclonal antibody prophylaxis regime.  I guess Thailand will furnish long-term test subjects for AZ.

What is cilgavimab and tixagevimab?

Cilgavimab in combination with tixagevimab is an experimental medicine being studied for the prevention before exposure of COVID-19. It is not yet known if cilgavimab and tixagevimab is safe and effective.
Source: drugs.com

"Tixagevimab/cilgavimab, sold under the brand name Evusheld is a combination of two human monoclonal antibodies, tixagevimab and cilgavimab targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections."
Source: Wikipedia

FDA info
https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing

Edited September 23, 2022 by connda

[connda]

Trial data.  But what the hay.  The rewards outweigh the risks.  Get those shots today! 

https://www.evusheld.com/en/hcp/clinicaldata

[onthedarkside]

Two off-topic posts have been removed.

 

[TallGuyJohninBKK]

An update from the U.S. FDA regarding issues for Evusheld's lessened effectiveness against a newer, emerging COVID variant:

 

October 04, 2022

 

FDA: Evusheld may lack efficacy against upcoming COVID-19 subvariants

 

Evusheld demonstrates reduced protection against the omicron subvariant BA.4.6, resulting in an increased risk for infection in those exposed to that COVID-19 strain, according to an updated FDA fact sheet.

...

Specifically, the fact sheet references the omicron subvariant BA.4.6, which, according to the FDA, has shown greater than 1,000-fold reduction in susceptibility to tixagevimab/cilgavimab, which is authorized for emergency use for pre-exposure prophylaxis of COVID-19

...

“Use of Evusheld is not a substitute for COVID-19 vaccination, and individuals for whom COVID-19 vaccination is recommended should get vaccinated,” the FDA statement said."

 

https://www.healio.com/news/rheumatology/20221004/fda-evusheld-may-lack-efficacy-against-upcoming-covid19-subvariants